Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Interpace Biosciences stock price, quote, forecast and news

IDXG
US46062X3035
A2PYCU

Price

1.62
Today +/-
+0.15
Today %
+10.64 %
P

Interpace Biosciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Interpace Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Interpace Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Interpace Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Interpace Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Interpace Biosciences Stock Price History

DateInterpace Biosciences Price
9/6/20241.62 undefined
9/5/20241.45 undefined
9/4/20241.45 undefined
9/3/20241.45 undefined
8/30/20241.45 undefined
8/29/20241.50 undefined
8/28/20241.57 undefined
8/27/20241.59 undefined
8/26/20241.60 undefined
8/23/20241.66 undefined
8/22/20241.45 undefined
8/21/20241.48 undefined
8/20/20241.46 undefined
8/19/20241.40 undefined
8/16/20241.41 undefined
8/15/20241.41 undefined
8/14/20241.26 undefined
8/13/20241.45 undefined
8/12/20241.33 undefined

Interpace Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Interpace Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Interpace Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Interpace Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Interpace Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Interpace Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Interpace Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Interpace Biosciences’s growth potential.

Interpace Biosciences Revenue, EBIT and net profit per share

DateInterpace Biosciences RevenueInterpace Biosciences EBITInterpace Biosciences Net Income
202340.21 M undefined2.8 M undefined802,000 undefined
202231.8 M undefined-3.6 M undefined-22 M undefined
202133.1 M undefined-5.4 M undefined-14.9 M undefined
202032.4 M undefined-26.1 M undefined-29.5 M undefined
201924.2 M undefined-23.9 M undefined-27.2 M undefined
201821.9 M undefined-12.6 M undefined-12.7 M undefined
201715.9 M undefined-6.3 M undefined-12.2 M undefined
201613.1 M undefined-3 M undefined-8.3 M undefined
20159.4 M undefined-22.9 M undefined-11.4 M undefined
20141.5 M undefined-15.7 M undefined-16.1 M undefined
2013146.5 M undefined-1.4 M undefined-4.6 M undefined
2012126.9 M undefined-1 M undefined-25.5 M undefined
2011157.3 M undefined-1.8 M undefined-11.9 M undefined
2010134.6 M undefined-4.9 M undefined-6.8 M undefined
200980.4 M undefined-10.4 M undefined-33.6 M undefined
2008105.2 M undefined-32.4 M undefined-34.5 M undefined
2007117.1 M undefined-12.9 M undefined-10 M undefined
2006239.2 M undefined5.1 M undefined11.8 M undefined
2005305.2 M undefined-2.8 M undefined-19.5 M undefined
2004345.8 M undefined37 M undefined21.1 M undefined

Interpace Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
8818337511917441671630734434530523911710580134157126146191315212432333140
--125.0083.33127.2758.6746.22139.0872.12-57.1212.050.29-11.59-21.64-51.05-10.26-23.8167.5017.16-19.7515.87-99.32800.0044.4415.3840.0014.2933.333.13-6.0629.03
37.5025.0016.6715.1525.3326.0525.2926.9218.859.4525.8726.6717.0523.0126.501.9030.0019.4020.3820.6315.75-22.2246.1553.3352.3833.3331.2554.5558.0657.50
323519314411213529899252553122426322623026811810181823
0000-49154012-472237-25-12-32-10-4-1-1-1-15-22-3-6-12-23-26-5-32
-----5.337.568.629.621.68-15.316.4010.72-0.662.09-10.26-30.48-12.50-2.99-0.64-0.79-0.68-1,500.00-244.44-23.08-40.00-57.14-95.83-81.25-15.15-9.685.00
0000-3910276-301221-1911-10-34-33-6-11-25-4-16-11-8-12-12-27-29-14-220
------400.0011.11170.00-77.78-600.00-140.0075.00-190.48-157.89-190.91240.00-2.94-81.8283.33127.27-84.00300.00-31.25-27.2750.00-125.007.41-51.7257.14-
0.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.20.21.62.83.744.14.24.36
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Interpace Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Interpace Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                       
2.45.859.459.5113.9167.472.7114.6109.597.6114.710790.272.662.964.554.947.623.28.40.615.26.12.32.83.14.83.5
4.95.81231.287.559.544.144.930.133.129.626.218.315.314.412.212.69.93.82.82.23.49.510.386.254.98
0000000006.21.9003.3000021.40.30000000
000036.40.40.600000000000000001.82.11.81.21.23
00.32.43.814.237.732.221.515.914.110.57.64.55.23.43.74.15.215.86.61.11.22.12.11.21.21.10.61
7.311.973.894.5252265149.6181155.5151156.7140.811396.480.780.471.662.744.819.24.219.817.716.514.112.312.110.32
0.40.53.13.7102118.314.517.216.112.88.35.43.53.92.52.41.61.81.50.90.70.810.711.710.42.92.65
00000000000000001.80.40000000000
0000000000000000000000000000
0000002.31.619.517.31614.713.42.510.47.30047.343.536.433.112.515.811.47.30.90
00000011.111.123.813.113.613.613.65.12418.92.5015.500008.48.48.400
000.54.88.316.59.711.28.82.72.52.23.62.15.44.30.24.46.43.60.300000.200.05
0.40.53.68.518.337.541.438.469.349.244.938.83613.243.7336.96.47148.637.633.813.334.931.526.33.82.7
7.712.477.4103270.3302.5191219.4224.8200.2201.6179.6149109.6124.4113.478.569.1115.867.841.853.63151.445.638.615.913.02
                                                       
0.10.10.10.10.10.10.10.10.10.10.20.20.20.20.20.20.20.20.20.200.30.326.646.946.946.946.94
04.247.647.497.2103.7106.7109.5116.7118.3119.2120.4121.9123.3124.8126.7128.5130.2134.2132.5127.7173.1175.8182.5184.4186.1187.5188.15
-1.1-5.24.914.641.74817.229.550.631.24333-1.4-35-41.8-53.7-79.3-83.8-99.9-111.3-119.6-131.8-159-185.7-212.1-227.1-249-248.22
0-100-1,500-1,300-800-800-700-600-2,000-80010000000000000000000
0000000000000000000000000000
-1-151.160.8138.2151123.3138.5165.4148.8162.5153.6120.788.583.273.249.446.634.521.48.141.617.123.419.25.9-14.6-13.13
0.60.51.4631.39.55.48.77.25.73.92.82.323.34.13.42.22.21.62.30.41.14.74.52.71.11.54
4.36.315.717.676.1131.152.968.839.936.424.617.925.416.126.626.118.521.96.16.38.46.45.48.811.410.88.59.42
3.96.69.617.723.810.99.53.612.216.6168.53.76.813.415.914.57.325.314.35.61.32.23.62.12.12.31.41
00.10000000000000000000000002.50
00000000000000000001.20000.20.20.105.1
8.813.526.741.3131.2151.567.881.159.358.744.529.231.424.943.346.136.431.433.623.416.38.18.717.318.215.714.417.47
00000000000000000027.27.27.9003.10.19.511.24.24
0000.60.70.3000001.11.4000002.5000000000
000.30.30.200005.87.99.19.11011.57.86.45.232.524.111.15.679.49.99.17.16.44
000.30.90.90.30005.87.910.210.51011.57.86.45.262.231.3195.6712.51018.618.310.68
8.813.52742.2132.1151.867.881.159.364.552.439.441.934.954.853.942.836.695.854.735.313.715.729.828.234.332.728.16
7.812.578.1103270.3302.8191.1219.6224.7213.3214.9193162.6123.4138127.192.283.2130.376.143.455.332.853.247.440.218.115.03
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Interpace Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Interpace Biosciences's financial health and stability.

Assets

Interpace Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Interpace Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Interpace Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Interpace Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
00-3910276-301221-1911-9-34-33-6-11-25-4-16-11-8-12-12-26-26-14-21
0000124765555421321254334552
00000-4-198-396210-10000-5-10000000
0324-6-882-7223-10-2-2-511-5193-12-2-4-60-7-3-250-3
0040026-1231312122272516-5-50351114
0000000000000000000030000000
000171818497100000000000000000
0231551980-884128319-6-15-15161-10-3-16-19-8-15-8-18-13-8-7
000-2-1-7-15-4-1-8-5-1-10-1-20-1-1-200000-100
000-3-4-14-31-65-6518-65606-1-260-1-3-2526000-13-106
000-1-3-6-15-27-5724-636170-2300-1-2226000-13006
0000000000000000000000000000
001-2010000000000000000003-3173
000460452223-1100000000001290321900
001370462223-110000000019-211290291683
000-600000000000000019-21000-60-80
0000000000000000000000000000
0244905151-9349-329-4553-9-17-91-11-7-22-14-714-9-3101
-0.372.532.8912.854.1511.2464.57-92.9939.820.88-2.7117.92-7.19-16.39-17.714.221.65-11.4-5.33-19.23-20.19-8.94-15.29-9.12-19.09-15.56-9.07-8.01
0000000000000000000000000000

Interpace Biosciences stock margins

The Interpace Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Interpace Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Interpace Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Interpace Biosciences's sales revenue. A higher gross margin percentage indicates that the Interpace Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Interpace Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Interpace Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Interpace Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Interpace Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Interpace Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Interpace Biosciences Margin History

Interpace Biosciences Gross marginInterpace Biosciences Profit marginInterpace Biosciences EBIT marginInterpace Biosciences Profit margin
202359.44 %6.97 %1.99 %
202257.23 %-11.32 %-69.18 %
202156.8 %-16.31 %-45.02 %
202033.02 %-80.56 %-91.05 %
201934.3 %-98.76 %-112.4 %
201853.42 %-57.53 %-57.99 %
201753.46 %-39.62 %-76.73 %
201648.85 %-22.9 %-63.36 %
201526.6 %-243.62 %-121.28 %
201413.33 %-1,046.67 %-1,073.33 %
201316.04 %-0.96 %-3.14 %
201221.2 %-0.79 %-20.09 %
201120.66 %-1.14 %-7.57 %
201019.76 %-3.64 %-5.05 %
200930.47 %-12.94 %-41.79 %
20082 %-30.8 %-32.79 %
200726.99 %-11.02 %-8.54 %
200623.33 %2.13 %4.93 %
200517.17 %-0.92 %-6.39 %
200426.78 %10.7 %6.1 %

Interpace Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The Interpace Biosciences earnings per share therefore indicates how much revenue Interpace Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Interpace Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Interpace Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Interpace Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Interpace Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Interpace Biosciences Revenue, EBIT and net profit per share

DateInterpace Biosciences Sales per ShareInterpace Biosciences EBIT per shareInterpace Biosciences Earnings per Share
20239.21 undefined0.64 undefined0.18 undefined
20227.57 undefined-0.86 undefined-5.24 undefined
20218.07 undefined-1.32 undefined-3.63 undefined
20208.1 undefined-6.53 undefined-7.38 undefined
20196.54 undefined-6.46 undefined-7.35 undefined
20187.82 undefined-4.5 undefined-4.54 undefined
20179.94 undefined-3.94 undefined-7.63 undefined
201665.5 undefined-15 undefined-41.5 undefined
201547 undefined-114.5 undefined-57 undefined
201415 undefined-157 undefined-161 undefined
20131,465 undefined-14 undefined-46 undefined
20121,269 undefined-10 undefined-255 undefined
20111,573 undefined-18 undefined-119 undefined
20101,346 undefined-49 undefined-68 undefined
2009804 undefined-104 undefined-336 undefined
20081,052 undefined-324 undefined-345 undefined
20071,171 undefined-129 undefined-100 undefined
20062,392 undefined51 undefined118 undefined
20053,052 undefined-28 undefined-195 undefined
20043,458 undefined370 undefined211 undefined

Interpace Biosciences business model

Interpace Biosciences is one of the most popular companies on Eulerpool.com.

Interpace Biosciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Interpace Biosciences historical P/E ratio, EBIT, and P/S ratio.

Interpace Biosciences shares outstanding

The number of shares was Interpace Biosciences in 2023 — This indicates how many shares 4.364 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Interpace Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Interpace Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Interpace Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Interpace Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Interpace Biosciences Stock splits

In Interpace Biosciences's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Interpace Biosciences.

Interpace Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20230 0.09  (0 %)2023 Q2
9/30/2022-0.26 -3.35  (-1,213.73 %)2022 Q3
6/30/2022-0.53 -0.93  (-75.34 %)2022 Q2
3/31/2022-0.82 -0.56  (31.37 %)2022 Q1
12/31/2021-0.33 -0.9  (-175.74 %)2021 Q4
9/30/2021-0.63 -0.85  (-34.41 %)2021 Q3
6/30/2021-1.03 -0.9  (12.64 %)2021 Q2
3/31/2021-1.46 -1.03  (29.38 %)2021 Q1
12/31/2020-1.07 -2.01  (-88.57 %)2020 Q4
9/30/2020-1.22 -1.54  (-26.07 %)2020 Q3
1
2
3
4
5
...
10

Interpace Biosciences list of shareholders

%
Name
Stocks
Change
Date
5.69476 % Singer (Douglas Mark)250,000-105,16512/31/2023
17.81221 % Kamin (Peter H)781,95609/15/2023
1.28749 % Burnell (Thomas W)56,52109/15/2023
0.58934 % McCarthy (Christopher)25,87210,0002/1/2024
0.42731 % Gorman (Robert J.)18,75909/15/2023
0.05601 % Sullivan (Stephen J)2,45909/15/2023
0.04002 % Keegan (Joseph D)1,75709/15/2023
0 % Manulife Investment Management (North America) Limited0-2768/31/2022
0 % Rocca (Fortunato Ron)0-9,3344/15/2023
1

Interpace Biosciences Executives and Management Board

Dr. Thomas Burnell61
Interpace Biosciences President, Chief Executive Officer, Director (since 2020)
Compensation 634,169
Dr. Vijay Aggarwal74
Interpace Biosciences Independent Director
Compensation 171,890
Dr. Joseph Keegan70
Interpace Biosciences Independent Director
Compensation 50,000
Mr. Stephen Sullivan76
Interpace Biosciences Independent Director (since 2004)
Compensation 50,000
Mr. Fortunato Rocca62
Interpace Biosciences Independent Director
Compensation 40,000
1
2

Most common questions regarding Interpace Biosciences

What is the P/E ratio of Interpace Biosciences 2024?

The P/E ratio cannot be calculated for Interpace Biosciences at the moment.

What is the P/S ratio of Interpace Biosciences 2024?

The P/S cannot be calculated for Interpace Biosciences currently.

What is the AlleAktien quality score of Interpace Biosciences?

The AlleAktien quality score for Interpace Biosciences is 3/10.

What is the revenue of Interpace Biosciences 2024?

The revenue cannot currently be calculated for Interpace Biosciences.

How high is the profit of Interpace Biosciences 2024?

The profit cannot currently be calculated for Interpace Biosciences.

What is the business model of Interpace Biosciences

No history available for Interpace Biosciences.

What is the Interpace Biosciences dividend?

Interpace Biosciences pays a dividend of 0 USD distributed over payouts per year.

How often does Interpace Biosciences pay dividends?

The dividend cannot currently be calculated for Interpace Biosciences or the company does not pay out a dividend.

What is the Interpace Biosciences ISIN?

The ISIN of Interpace Biosciences is US46062X3035.

What is the Interpace Biosciences WKN?

The WKN of Interpace Biosciences is A2PYCU.

What is the Interpace Biosciences ticker?

The ticker of Interpace Biosciences is IDXG.

How much dividend does Interpace Biosciences pay?

Over the past 12 months, Interpace Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Interpace Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Interpace Biosciences?

The current dividend yield of Interpace Biosciences is .

When does Interpace Biosciences pay dividends?

Interpace Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Interpace Biosciences?

Interpace Biosciences paid dividends every year for the past 0 years.

What is the dividend of Interpace Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Interpace Biosciences located?

Interpace Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Interpace Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Interpace Biosciences from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Interpace Biosciences pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Interpace Biosciences in the year 2023?

In the year 2023, Interpace Biosciences distributed 0 USD as dividends.

In which currency does Interpace Biosciences pay out the dividend?

The dividends of Interpace Biosciences are distributed in USD.

All fundamentals about Interpace Biosciences

Our stock analysis for Interpace Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Interpace Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.